Eli Lilly and Company (LLY)
Verdict history · LLY
Every call Verdix has made on LLY.
While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
See methodology for how verdicts are produced. Full track record →
Why the panel isn’t ready to call LLY yet — and where they disagree.
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
NYSE · Health Care / Pharmaceuticals · 2026-08-08 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
WaitHIGH confidence
Why
Eli Lilly's GLP-1 franchise earns universal respect from our panel for its world-class margins and growth trajectory, but at $1,185 — essentially dead-on fair value per The Intrinsic-Value Modeler's base-case DCF — every archetype agrees the price leaves no room for error. The debate is not whether Lilly is a great business (it is), but whether the current multiple can survive the competition and patent cliffs already visible on the horizon. Our panel lands at a high-conviction WAIT: own it if you have it, but don't chase it here.Level to watch
Key resistance 1,249.45+5.4% from 1,185.71
Next catalyst
Trigger to confirm the breakout: A decisive weekly close above $1,249.45 on strong volume would confirm the Stage 2 uptrend's next leg and shift cautious voices toward buying the momentum rather than waiting for a pullback.The panel's take
Verdict: WAIT · Conviction: HIGH · Last price: 1185.71
The cautious camp is dominated by PRICE/TIMING objections, not BUSINESS objections. The Intrinsic-Value Modeler, Fisher, The Asymmetric Bargainer, and even the technical-scout all explicitly endorse the quality of the business — The Intrinsic-Value Modeler's base-case DCF lands at $1,180, Fisher scores it 15/15, and The Asymmetric Bargainer calls the margins "world-class." Only The Forensic Skeptic raises a genuine business-level objection (leverage risk, patent cliff). The BUY vs WAIT split (The GARP Operator/Bullish voices vs. Technical/Fundamental/Value cautious voices) is structurally a WAIT, not a HOLD, because the cautious voices want the same great business at a better price. The specific trigger is clear: a pullback to $1,110-$1,116 (weekly EMA20/23.6% Fib) or a confirmed breakout above $1,249.45.
Key levels
Key levels · LLY
USD · as of 2026-08-08Analyst consensus target 1,185.71 USD · range 1,185.71–1,185.71
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
What legendary investors think
We ran Eli Lilly and Company past a panel of 6 legendary investors' frameworks.
The panel · 6 investors
The GARP OperatorGrowth (GARP)🟢 BullishMed
Signal: With a PEG of 1.29 on 30.3% expected EPS growth, the stock clears The GARP Operator's PEG-below-1.5 rule and is a bargain for a Fast Grower of this quality, especially given operating cash flow ($28.1B) that handily exceeds net income ($26.7B). Conviction: Conviction is pushed up by three independent, hard-to-dispute facts: PEG well below 1.5, cash flow exceeding earnings, and management raising full-year guidance to $85–87 billion — all confirming the growth story is real, not accounting.
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralMed
Signal: The base-case DCF lands at $1,180 per share — essentially dead-even with the current $1,185.71 price, leaving zero margin of safety and pricing in a plausible but not conservative outcome. Conviction: Conviction is held back by one unresolved dependency: the entire valuation hinges on whether revenue growth decelerates gracefully to 20% or collapses to 15% sooner — the bear case drops fair value to $850, a 28% haircut.
The Scuttlebutt Growth InvestorGrowth/Management⚫ NeutralMed
Signal: The company scores a perfect 15/15 on Fisher's checklist — a rare and beautiful bird — with particular strength in market potential, R&D effectiveness, and long-range management outlook. Conviction: Conviction is tempered by a single contested assumption: point 11 (competitive advantages) is rated 'eroding,' and Fisher would require constant monitoring of whether the moat is actually strengthening or weakening as oral GLP-1 competitors advance.
The Quality RationalistMental Models/Quality⚫ NeutralMed
Signal: The business earns a 102% ROE and 33.5% net margins without excessive leverage, but The Quality Rationalist would rather pay a premium for a widening moat than a shrinking one — and Lilly's moat is eroding, not widening. Conviction: Conviction is held back by the absence of any open-market insider buying at these levels combined with a put/call ratio of 2.48x — the people closest to the business are hedging, not betting on perfection.
The Asymmetric BargainerContrarian/Deep Value⚫ NeutralMed
Signal: The Dhandho test returns only 2/4 passed: a 35% probability of a 30–40% loss swamps a 20% chance of a home run, producing an expected value near zero — this is not a 'heads I win, tails I don't lose much' setup. Conviction: Conviction is held back by the asymmetric downside: at 40x earnings with $45B in net debt, a 20% earnings miss compounds into a potential 40–50% stock decline, and the CEO's own euphoria ('never brighter') is a contrarian warning flag.
The Forensic SkepticContrarian/Forensic🔴 BearishMed
Signal: Normalized intrinsic value using a conservative 18x multiple on $30 EPS lands at $540 — less than half the current price — meaning the market is pricing in a decade of uninterrupted GLP-1 dominance that may never materialize. Conviction: Conviction is pushed up by multiple independent red flags: a 2.48x put/call ratio, zero insider buying, 79% analyst bullishness signaling a dangerously crowded trade, and $45B of net debt leveraged against a growth bet that assumes no competitive disruption.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- All six archetypes agree the underlying business is exceptional — 83.4% gross margins, 49.7% operating margins, 33.5% net margins, and a dominant GLP-1/GIP franchise with tirzepatide (Mounjaro/Zepbound) are world-class.
- All agree tirzepatide's commercial trajectory and the retatrutide pipeline represent genuine, high-quality growth with multi-year visibility.
- All agree the current $1,185 price offers no margin of safety — even the bullish GARP Operator acknowledges the stock is 'paying a fair price' rather than a bargain, and the Intrinsic-Value Modeler's DCF lands within $6 of the current quote.
- All agree a pullback to the $1,110–$1,120 zone (weekly EMA20 / 23.6% Fibonacci) would dramatically improve the upside-versus-downside profile and satisfy the price-sensitive cautious camp.
The real debate
- The GARP Operator sees a PEG of 1.29 as reasonable for 30%+ earnings growth and worth acting on, while the Forensic Skeptic sees the same 40x trailing P/E as evidence of a dangerously crowded trade where normalized value is less than half the current price.
- The Scuttlebutt Growth Investor scores the business a perfect 15/15 yet flags the moat as eroding, while the Quality Rationalist explicitly states he would rather pay a premium for a widening moat (like Costco) than a shrinking one — same data, opposite willingness to pay.
- The Intrinsic-Value Modeler's base case lands at $1,180 (essentially fair value), but his bear case drops to $850 (−28%), while the Asymmetric Bargainer's expected-value framework shows the 35% downside probability outweighing the 20% upside — both see the same narrow gap between price and value but disagree on whether the asymmetry is tolerable.
The question it comes down to: Can Eli Lilly sustain 25%+ revenue growth for five years and keep operating margins above 45% in the face of intensifying competition from Novo Nordisk, oral GLP-1 entrants, and eventual patent cliffs — or is the market already pricing in that outcome at 40x trailing earnings?
The bottom line
- Trigger to confirm the breakout: A decisive weekly close above $1,249.45 on strong volume would confirm the Stage 2 uptrend's next leg and shift cautious voices toward buying the momentum rather than waiting for a pullback.
- Pullback to watch: A retracement to the $1,110–$1,116 zone (weekly EMA20 / 23.6% Fibonacci) would compress the forward P/E toward 27x and satisfy the price-sensitive cautious camp's demand for a margin of safety.
- Next catalyst: Retatrutide's BLA submission (planned Q1 2027) and subsequent FDA review will either validate the pipeline narrative supporting a $1,400+ fair value or crack the growth story underpinning the current valuation.
- Risk to monitor: Any Phase 3 data from Novo Nordisk's CagriSema or an oral competitor showing superiority over tirzepatide would directly challenge the moat and could trigger the 30–40% downside the bearish voices warn about.
- Further out: A monthly close below $973 (monthly EMA20) would break the multi-year Stage 2 uptrend and flip the technical picture from 'wait for support' to 'trend broken' — the sell trigger the cautious camp is watching.
contact@verdixhq.com · Published 2026-08-08 · Prices as of 2026-08-08 · Time horizon: 3–12 months · No direct position held in LLY · LLY verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel also debated